Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: Practical strategy for the breast cancer therapy

Synthesis and assessment of the antioxidant and antitumor properties of asymmetric curcumin analogues

“…The synthetic routes for the compounds of the mono-carbonyl analogs of curcumin (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26) used in this study are shown in Schemes 1 and scheme 2; their structures are shown in Table 1. The compounds 15 -26 were prepared as asymmetric analogues(scheme2) and the symmetric compounds 10-14 were also synthesized according to the literature [ 20 ] [ 21 ] .…”

pH-controlled Release System for Curcumin based on Functionalized Dendritic Mesoporous Silica Nanoparticles

“…As curcumin is a promising pro-drug, a few studies have been reported recently on curcumin delivery based on MSNs. Their aim was to enhance the cytotoxicity of curcumin and exploit the effect of surface functionality on cellular uptake and anticancer activity when utilizing the MCM-41 type [35,36], as well as curcumin-loaded guanidine for combating breast cancer using KIT-6 silica type [37] and controlled release of curcumin from hollow silica material [38,39]. However, to the best of our knowledge no reports on utilization of KCC-1 silica type in delivery of curcumin as model anticancer natural pro-drugs yet reported, and also no comparative study to analyze the differences between the KCC-1 material and commonly used MCM-41 type in controlled release of the small molecule drugs has been carried out.…”

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

“…-KB-V1 -Specific binding with cell was higher -Improved anticancer activity [88] Conjugated with (P-gp) antibody -KB-V1 -Decreased cell viability and tumor growth [89] -Human osteosarcoma U2OS cells -Enhanced cellular uptake -Elevated activity and expression of caspases-3/-7 and caspase-9 -Down regulated expression level of p-Akt -High drug loading capacity -Highly programmed release of CUR -Long-term anticancer efficacy [93] -HT-29 cell -Double inhibition of the cancerous cells compared to CUR [94] Coated with Chitosan -HepG2 -Huh7 -Bel7402…”

“…Furthermore, PLGA-CUR NPs can effectively inhibit proliferation and colony formation ability of prostate cancer cells than free CUR and showed superior tumor regression compared to free CUR in xenograft mice [21]. CUR-loaded guanidine functionalized in PEGylated mesoporous silica NPs was synthesized by Mamani et al [93]. It showed pH-sensitive controlled characteristics and highly programmed release of CUR leading to the satisfactory results in in-vitro breast cancertherapy [93].…”

“…CUR-loaded guanidine functionalized in PEGylated mesoporous silica NPs was synthesized by Mamani et al [93]. It showed pH-sensitive controlled characteristics and highly programmed release of CUR leading to the satisfactory results in in-vitro breast cancertherapy [93]. Similarly, Prajakta et al [94] demonstrated that there was almost double inhibition of the cancerous cells by CUR loaded Eudragit S100 NPs in HT-29 cell lines [94].…”